TGen, Genomic Health ID Potential Oxaliplatin Response Genes; Findings May Enhance Colon Cancer Test | GenomeWeb

By Turna Ray

A preliminary study conducted by Genomic Health and the Translational Genomics Research Institute suggests that certain genes may help explain why colon cancer patients have varying responses to the commonly prescribed chemotherapeutic oxaliplatin.

The results of this trial, if confirmed in additional studies, may help Genomic Health add a treatment benefit indication to its Oncotype DX test for colon cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.